Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Pacira BioSciences, Inc. (PCRX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $726.4M | $701.0M | $675.0M | $666.8M | $541.5M | $429.6M | $418.9M | $332.4M | $284.3M | $270.1M | $249.0M | $197.7M | $85.6M | $39.1M | $15.7M | $14.6M | $15.0M |
| Research & development | $117.3M | $81.6M | $76.3M | $84.8M | $55.5M | $59.4M | $72.1M | $55.7M | $57.3M | $45.7M | $28.7M | $18.7M | $21.6M | $9.9M | $14.9M | $18.6M | $26.2M |
| Operating expenses | — | — | — | — | — | — | $410.5M | $321.4M | $311.6M | $308.4M | $239.5M | $202.8M | $138.8M | $88.4M | $54.8M | $37.3M | $43.6M |
| Operating income | $19.2M | −$73.4M | $87.7M | $60.0M | $89.9M | $46.4M | $10.5M | $15.9M | −$24.9M | −$32.0M | $9.5M | −$5.2M | −$53.3M | −$49.3M | −$39.1M | −$22.7M | −$28.5M |
| EBITDAderived | $110.2M | $5.4M | $163.2M | $151.5M | $118.5M | $66.3M | $30.1M | $29.1M | −$11.1M | −$19.1M | $20.9M | $4.9M | −$47.5M | −$43.6M | −$34.8M | −$18.6M | −$24.4M |
| Net income | $7.0M | −$99.6M | $42.0M | $15.9M | $42.0M | $145.5M | −$11.0M | −$471,000 | −$42.6M | −$37.9M | $1.9M | −$13.7M | −$63.9M | −$52.3M | −$43.3M | −$27.1M | −$31.7M |
| Basic EPSper diluted share | $0.16 | -$2.15 | $0.91 | $0.35 | $0.95 | $3.41 | -$0.27 | -$0.01 | -$1.07 | -$1.02 | $0.05 | -$0.39 | -$1.93 | -$1.72 | -$2.64 | -$47.29 | -$55.32 |
| Diluted EPSper diluted share | $0.16 | -$2.15 | $0.89 | $0.34 | $0.92 | $3.33 | -$0.27 | -$0.01 | -$1.07 | -$1.02 | $0.04 | -$0.39 | -$1.93 | -$1.72 | -$2.64 | -$47.29 | -$55.32 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 11, 2026Form 4 · 10b5-1 | RIKER LAURENSenior Vice President, Finance | SellCommon Stock | 6.1K | $23.50 | $143.7K | 62.3K |
| Jun 4, 2026Form 4 · 10b5-1 | WILLIAMS KRISTENChief Administrative Officer | SellCommon Stock | 10.3K | $22.27 | $228.5K | 167.1K |
| Apr 23, 2026Form 4 · 10b5-1 | Cross ShawnChief Financial Officer | SellCommon Stock | 12.9K | $25.16 | $325.6K | 105.3K |
| Apr 22, 2026Form 4 · 10b5-1 | Cross ShawnChief Financial Officer | SellCommon Stock | 1.5K | $25.01 | $37.5K | 105.3K |
| Apr 21, 2026Form 4 · 10b5-1 | Cross ShawnChief Financial Officer | SellCommon Stock | 2.8K | $25.01 | $71.2K | 105.3K |